TABLE 3.
SoC | Remdesivir | Incremental | |
---|---|---|---|
Total costs (CN¥) | 2 255 649 459 | 2 353 580 729 | 97 931 270 |
QALDs during the analytic period (QALY equivalent) | 512 651 191 (1 403 562) | 512 677 159 (1 403 634) | 25 968 (71) |
QALY loss due to death | 34 026 | 27 150 | 6875 |
QALY | NA | NA | 6947 |
ICER (CN¥/QALY) | NA | NA | 14 098 |
SoC, standard of care; QALD, quality‐adjusted life day; QALY, quality‐adjusted life year; ICER, incremental cost‐effectiveness ratio.